A Phase 2/3 interventional study of linsitinib in Thyroid Eye Disease, Graves Orbitopathy and Endocrine System Diseases, sponsored by Sling Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Sling Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 27th largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2023, is one of 3 in phase 2/3, reaches primary completion later than 5 of the 17 other live ones, and was the 26th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Poland, Spain and 1 more country
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 24 · Phase 4 5
First in 2006; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 84 across the 47 interventional studies, 100 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Sling Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Sling Therapeutics, Inc. has 3 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Ophthalmopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
| NCT07832136Viridian Therapeutics, Inc.An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | 2027-04 |
| NCT07623837THYROSCOPE INC.Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) | 2027-06-30 |
| NCT07623993THYROSCOPE INC.Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active Arm Low Dose Linsitinib
Drug: linsitinib
Active Arm High Dose Linsitinib
Drug: linsitinib
Study medication taken twice daily by mouth
Percentage of Subjects who are Proptosis Responders at Week 24
Percentage of subjects with a ≥ 2 mm reduction of proptosis from baseline as determined by exophthalmometer
Time frame: 24 weeks
Change from Baseline in Proptosis to Week 24 (Study Eye)
Change from baseline in reduction of proptosis from baseline as determined by exophthalmometer
Time frame: 24 weeks
Percentage of Subjects who are Overall Responders at Week 24
Percentage of Subjects with a response of ≥ 2 mm reduction of proptosis at Week 24 as determined by exophthalmometer
Time frame: 24 weeks
Percentage of Subjects who are CAS Categorical Responders at Week 24 (Study Eye)
Time frame: 24 weeks
Change from Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24
Time frame: 24 weeks
Started Oct 2023 (actual). Primary completion is estimated for Jun 2026, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linsitinib
Sling Therapeutics, Inc.